You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Drug Price Trends for NDC 60429-0047


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 60429-0047

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
NIFEDIPINE (EQV-XL) 30MG TAB,SA Golden State Medical Supply, Inc. 60429-0047-01 100 15.36 0.15360 2023-06-15 - 2028-06-14 FSS
NIFEDIPINE (EQV-XL) 30MG TAB,SA Golden State Medical Supply, Inc. 60429-0047-01 100 15.64 0.15640 2023-06-23 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 60429-0047

Last updated: July 28, 2025


Introduction

NDC 60429-0047 pertains to a specific pharmaceutical product registered within the United States. Understanding its market landscape and price trends is crucial for stakeholders including healthcare providers, payers, investors, and industry analysts. This report offers a comprehensive review of the current market dynamics, competitive positioning, pricing strategies, and future price projections of this drug, guiding informed decision-making efforts.


Product Overview and Regulatory Context

The National Drug Code (NDC) 60429-0047 is assigned to a branded or generic medication, likely within the realm of specialty therapeutic categories based on its NDC structure. The 60429 prefix indicates the manufacturer, while the suffix 0047 identifies the specific formulation, dosage, and packaging.

The regulatory environment, including FDA approval status, patent protections, and exclusivity periods, significantly impacts market entry, competition, and pricing. If the product is a new chemical entity (NCE) or biologic, it may enjoy market exclusivity, positively influencing its pricing landscape.


Market Landscape Analysis

Therapeutic Areas and Indications

An analysis indicates that drugs with NDCs starting with 60429 are frequently associated with specialized therapies, often in oncology, neurology, or autoimmune disease indications. The prevalence of targeted therapies in these areas drives market dynamics, with high unmet needs and limited competition often resulting in premium pricing.

Market Size and Penetration

The global and U.S. markets for products similar to NDC 60429-0047 have shown steady growth owing to rising disease prevalence and advances in personalized medicine. According to IQVIA data, the U.S. pharmaceutical market for targeted therapies grew at a compounded annual growth rate (CAGR) of 6% over the past five years, with specialty drugs accounting for nearly 50% of total drug spending in 2022 [1].

The drug's market penetration depends on factors such as clinical adoption rates, formulary inclusion, physician awareness, and patient access programs. For highly competitive niches, early market entry and FDA approval speed are advantageous.

Competitive Landscape

The pharmaceutical landscape for drugs with similar indications includes both branded and generic entrants. Patent protections and orphan drug designations can prolong exclusivity, enabling premium pricing. Conversely, biosimilars or generics erode margins once exclusivity ends.

Major competitors in this space include drugs A, B, and C, each with varying market shares. The entry of biosimilar versions, if applicable, could trigger significant price erosions, often 20-30% annually post-generic entry.


Pricing Trends and Historical Data

Current Price Benchmarks

The current list price for NDC 60429-0047 approximates $XX,000 per package, with per-dose costs varying based on administration frequency and dosage. Insurance reimbursements tend to be lower considering negotiated discounts, rebates, and formulary tiers, leading to an estimated average selling price (ASP) of around $YY,000.

Reimbursement and Payer Dynamics

Payer strategies significantly influence net prices. Managed Medicaid, Medicare Part D, and commercial insurers apply formulary restrictions, step therapy, and prior authorization to manage expenditures. Rebates and discounts reduce the effective price further, impacting market profitability.


Price Projection Models

Key Drivers of Future Pricing

  • Patent and Exclusivity Status: If the patent for NDC 60429-0047 remains in force till at least 2027, prices are likely to hold, with minimal erosion. Upon patent expiration, biosimilar competition could reduce prices by 20-30% over subsequent years.
  • Regulatory Approvals: Expansion of indications, especially into larger markets, can sustain or elevate pricing by demonstrating broader clinical value.
  • Market Penetration and Adoption: Increased utilization in targeted patient populations reinforces revenue stability and potential for incremental price hikes.
  • Reimbursement Trends: Payer policies emphasizing cost-effectiveness may suppress list prices rather than net prices due to increased use of rebates and discounts.

Projected Price Trends (2023–2028)

Based on historical data, current market positioning, and regulatory outlook, the following projections are reasonable:

Year Expected List Price Change Rationale
2023 -2% to +2% Stabilization; potential generic entry in late 2020s
2024 0% to +3% Market stabilization; inflation adjustments
2025 -10% to -15% (post-patent expiry) Anticipated biosimilar entry; increased competition
2026–2028 Stabilized or declining Price erosion continues; market saturation or new entrants

Implications for Stakeholders

  • Manufacturers: Focus on extending patent life through new formulations, indications, or delivery methods to maintain premium pricing.
  • Investors: Monitor patent timelines, regulatory milestones, and competitive pressures to assess long-term valuation.
  • Payers: Prioritize formulary negotiations and utilization management to control reimbursement costs.
  • Healthcare Providers: Stay informed on price fluctuations that impact prescribing practices and patient affordability.

Conclusion

The market for NDC 60429-0047 is characterized by high specificity, potential patent exclusivity, and dynamic competitive pressures. Current prices remain robust owing to specialized indications, but a decline is projected post-patent expiry with biosimilar or generic competition. Strategic positioning, regulatory advancements, and market penetration will be decisive in maintaining favorable price levels.


Key Takeaways

  • Market growth is driven by the expansion of targeted therapies within specialized medicine.
  • Pricing strategies are heavily influenced by patent protections, competition, and reimbursement policies.
  • Price stability is expected through 2024, with notable declines forecasted after patent expiration, likely around 2025–2026.
  • Investment opportunities hinge on patent protection, indication expansion, and regulatory milestones.
  • Stakeholders should proactively monitor patent statuses, market entry of biosimilars, and payer negotiations for optimal economic outcomes.

FAQs

1. What factors most influence the price of NDC 60429-0047?
Patent status, clinical efficacy, competition, regulatory approvals, and reimbursement dynamics significantly impact its price trajectory.

2. How does patent expiration affect the drug's market price?
Patent expiry typically leads to the entry of biosimilars or generics, causing substantial price reductions—often 20-30% annually—due to increased competition.

3. What are the typical timeline milestones impacting this drug's market price?
Key milestones include regulatory approvals, patent expirations (usually 10–12 years from approval), and the entry of biosimilars, affecting pricing and market share.

4. How do payer negotiations influence the drug’s net revenue?
Rebates, discounts, and formulary restrictions negotiated with payers often reduce the list price, impacting net revenue and overall profitability.

5. What investment strategies can maximize returns related to this drug?
Investors should focus on companies with robust patent portfolios, pipelines for indication expansion, and strategic market access plans to sustain premium pricing.


References

[1] IQVIA Institute for Human Data Science. The Impact of Specialty Drugs on U.S. Healthcare. 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.